Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced that its affiliate has completed the divestiture of the Sprout Pharmaceuticals subsidiary to Sprout2 Inc., an entity …
This 50 billion-dollar fund is dropping VRX and turning to TEVA.
Mizuho’s Irina Rivkind Koffler cannot “justify” changing her rating on Valeant. Instead, the analyst lifts her price target by 40%; Here’s why.
J.P.
Why this Wall Street hedge fund legend sold VRX and GILD?
This billion-dollar hedge fund initiates new position in struggling pharma TEVA as exits VRX.
Is Billionaire fund guru Jim Simons switching OPK for VRX?
BTIG’s Tim Chiang still spots challenges in VRX’s orbit, but likewise pinpoints strength in eyecare business Bausch + Lomb, which boasts robust international gains.
Ken Griffin is a man known to be raring to take a risk when it is worthwhile, a daring and strategic mindset that …
One of the world’s top fund managers is backing volatile healthcare stocks VRX and MNKD.
